HLD 0915
Alternative Names: HLD-0915Latest Information Update: 13 Feb 2025
Price :
$50 *
At a glance
- Originator Halda Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 31 Jan 2025 Phase-I/II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06800313)
- 30 Jan 2025 Halda Therapeutics plans a phase I/II trial for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (PO) in February 2025 (NCT06800313)
- 12 Aug 2024 Preclinical trials in Prostate cancer (Metastatic disease, Hormone refractory) in USA (PO)